Effects of intrauterine devices on female sexual function: a cross-sectional study

Yıl 2022, Cilt: 8 Sayı: 5, 606 - 611, 04.09.2022

Feyza Bayram , Nergis Kender Erturk

https://doi.org/10.18621/eurj.1053425

Cited By: 1

Öz

Objectives: To examine the differences in sexual functions between women using copper intrauterine device (Cu-IUD) and levonorgestrel intrauterine system (LND-IUS).

Methods: A total of 125 women between the ages of 20 and 40 were included in the study. The demographic data of all participants were recorded. Female Sexual Function Index (FSFI) was performed to all participants. Study participants were divided into 3 groups; 42 Cu-IUD users, 42 LND-IUS users, and 41 control (not use contraceptive) group, then compared. Women with a total score lower than ≤ 26.5 were considered as having sexual dysfunction.

Results: The prevalence of female sexual dysfunction (FSD) was 56.8% among the participants. The total FSFI scores of Cu-IUD and LNG-IUS groups were similar. Moreover, the FSFI score of both IUD users was lower than the control group, and the difference was statistically significant (p < 0.001). The presence of Cu-IUD affected arousal more than pain, satisfaction, lubrication and orgasm scores (p = 0.016). Pain score was similar among IUD groups and significantly lower than controls (p < 0.001). Moreover, orgasm and satisfaction scores were found to be significantly higher in the control group than in the both IUD groups (p < 0.001). All of three groups were also similar about desire and lubrication domains of FSFI.

Conclusions: In conclusion, this study found that Cu-IUD and LNG-IUS users did not differ in terms of sexual function according to scores calculated by FSFI.

Anahtar Kelimeler

Female sexual dysfunction, female sexual function index, copper intrauterine device, levonorgestrel intrauterine device, sexuality

Kaynakça

• 1. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012;98:893-7.
• 2. Buhling KJ, Zite NB, Lotke P, Black K. Worldwide use of intrauterine contraception: a review. Contraception 2014;89:162-73.
• 3. Hubacher D, Chen PA, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009;79:356-62.
• 4. Koc I. Prevalence and sociodemographic correlates of consanguineous marriages in Turkey. J Biosoc Sci 2008:40;137-48.
• 5. Cim N, Soysal S, Sayan S, Yildizhan B, Karaman E, Cetin O, et al. Two years follow-up of patients with abnormal uterine bleeding after insertion of the levonorgestrel-releasing intrauterine system. Gynecol Obstet Invest 2018;83:569-75.
• 6. Skrzypulec V, Drosdzol A. Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system Mirena. Coll Antropol 2008;32:1059-68.
• 7. World Health Organization. Reproductive Health, Comprehensive cervical cancer control: a guide to essential practice. World Health Organization 2006.
• 8. Banaei M, Alidost F, Ghasemi E, Dashti S. A comparison of sexual function in primiparous and multiparous women. J Obstet Gynaecol 2020;40:411-8.
• 9. Jaafarpour M, Khani A, Khajavikhan J, Suhrabi Z. Female sexual dysfunction: prevalence and risk factors. J Clin Diagn Res 2013;7:2877-80.
• 10. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The female sexual function index (FSFI): a multidimensional self- report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-205.
• 11. Basson R, Althof S, Davis S, Fugl-Meyer K, Goldstein I, Leiblum S, et al, Summary of the recommendations on sexual dysfunction in women. J Sex Med 2004;1:24-34.
• 12. Öksüz E, Malhan S. Prevalence and risk factors for female sexual dysfunction in Turkish women. J Urol. 2006;175:654-8.
• 13. Cayan S, Akbay E, Bozlu M, Canpolat B, Acar D, Ulusoy E. The prevalence of female sexual dysfunction and potential risk factors that may impair sexual function in Turkish women. Urol Int 2004;72:52-7.
• 14. Koseoglu SB, Deveer R, Akin MN, Gurbuz AS, Kasap B, Guvey H. Is there any impact of copper intrauterine device on female sexual functioning? J Clin Diagn Res 2016;10:21-3.
• 15. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1-20.
• 16. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-9.
• 17. Ferreira J, Carreiro A, Fernandes A, Bahamondes L. Sexual function and quality of life in a cohort of Brazilian users of two kind of intra- uterine contraceptives. Res Bras Ginecol Obstet 2019;41:236-41.
• 18. IMoreira IFA, Bianchini MP, Moreira GRC, Almeida AM, Rezende BA. Sexual function and metabolic/hormonal changes in women using long-term hormonal and non-hormonal contraceptives: a pilot study. BMC Women’s Health 2020;20:240.
• 19. Malmborg A, Brynhildsen J, Hammar M. A survey of young women’s perceptions of the influence of the Levonorgestrel-Intrauterine System or copper-intrauterine device on sexual desire. Sex Reprod Healthc 2019;21:75-80.
• 20. Neri M, Piras B, Paoletti AM, Vallerino V, Corda V, Ronchetti C, et al. Long-acting reversible contraception (LARC) with the intrauterine sys- tem with levonorgestrel (6 mcg/d): observational study on the accept- ability, quality of life, and sexuality in Italian women. Gynecol Endocrinol 2018;34:532-5.
• 21. Sanders JN, Turok DK, Royer PA, Thompson IS, Gawron LM, Storck KE. One-year continuation of copper or levonorgestrel intrauterine devices initiated at the time of emergency contraception. Contraception 2017;96:99-105.
• 22. Bastianelli C, Farris M, Benagiano G. Use of the levonorgestrel- releasing intrauterine system, quality of life and sexuality. Experience in an Italian family planning center. Contraception 2011;84:402-8.
• 23. Gorgen H, Api M, Akca A, Cetin A. Use of the levonorgestrel-IUS in the treatment of menorrhagia: assessment of quality of life in Turkish users. Arch Gynecol Obstet 2009;27:835-40.
• 24. Casado-Espada NM, de Alarcon R, de la Iglesia-Larrad JI, Bote-Bonaechea B, Montejo AL. Hormonal contraceptives, female sexual dysfunction, and managing strategies: a review. J Clin Med 2019;8:908-10.
• 25. Sakinci M, Ercan CM, Olgan S, Coksuer H, Karasahin KE, Kuru O, et al. Comparative analysis of copper intrauterine device impact on female sexual dysfunction subtypes. Taiwanese J Obstet Gynecol 2016;55:30-4.
• 26. Elnashar AM, El-Dien Ibrahim M, El-Desoky MM, Ali OM, El-Sayd Mohamed Hassan M. Female sexual dysfunction in Lower Egypt. BJOG 2007;114:201-6.
• 27. Valadares AL, Pinto-Neto AM, Conde DM, Sousa MH, Osis MJ, A. Paiva LC. Population-based study of dyspareunia in a cohort of middle-aged Brazilian women. Menopause 2008;15:1184-90.